Across TCGA pan-cancer cohorts, STK38L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STK38L data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher STK38L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STK38L expression acts as an unfavorable survival marker.

UCEC, PRAD, and LUAD are the cancer types where STK38L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.258	0.787	.018	6	view →
LUSC	DFS	Median	All	0.165	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: STK38L tumor-vs-normal RNA expression · all STK38L data types